NeuroRx Says COVID-19 Drug Improves Survival If Overstretched ICUs Excluded

Will Seek EUA Shortly

Therapy shows some promise in helping COVID-19 respiratory failure patients but the US FDA may question company’s data cut. 

ICU Covid
NeuroRx argues that ICUs overwhelmed by COVID-19 cases should be excluded from the trial - but the US FDA may not agree • Source: Getty Images

NeuroRx believes it has a breakthrough treatment for critically ill COVID-19 patients, after unveiling Phase IIb/III data for its novel therapy Zyesami (aviptadil acetate) earlier this week. 

The small, privately held biopharma company unveiled trial data on 29 March which showed that the vasoactive intestinal polypeptide (VIP)...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip